Curcumin and cardiovascular diseases: Focus on cellular targets and cascades.


Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 20 08 2020
revised: 18 12 2020
accepted: 26 12 2020
pubmed: 16 1 2021
medline: 20 7 2021
entrez: 15 1 2021
Statut: ppublish

Résumé

Cardiovascular diseases (CVDs) are one of the leading causes of the most considerable mortality globally, and it has been tried to find the molecular mechanisms and design new drugs that triggered the molecular target. Curcumin is the main ingredient of Curcuma longa (turmeric) that has been used in traditional medicine for treating several diseases for years. Numerous investigations have indicated the beneficial effect of Curcumin in modulating multiple signaling pathways involved in oxidative stress, inflammation, apoptosis, and proliferation. The cardiovascular protective effects of Curcumin against CVDs have been indicated in several studies. In the current review study, we provided novel information on Curcumin's protective effects against various CVDs and potential molecular signaling targets of Curcumin. Nonetheless, more studies should be performed to discover the exact molecular target of Curcumin against CVDs.

Identifiants

pubmed: 33450488
pii: S0753-3322(20)31407-4
doi: 10.1016/j.biopha.2020.111214
pii:
doi:

Substances chimiques

Cardiovascular Agents 0
Curcumin IT942ZTH98

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

111214

Informations de copyright

Copyright © 2020. Published by Elsevier Masson SAS.

Auteurs

Ali Mohammad Pourbagher-Shahri (AM)

Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

Tahereh Farkhondeh (T)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences (BUMS), Birjand, Iran; Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran.

Milad Ashrafizadeh (M)

Faculty of Engineering and Natural Sciences, Sabanci University, Orta Mahalle, Üniversite Caddesi No. 27, Orhanlı, Tuzla, 34956 Istanbul, Turkey; Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, 34956, Istanbul, Turkey.

Marjan Talebi (M)

Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, 19968 35115, Iran.

Saeed Samargahndian (S)

Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran. Electronic address: samarghandians1@nums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH